Vol. 2 No. 8 (2022)
Reimbursement Reviews

Amifampridine phosphate (Firdapse)

Published August 25, 2022

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses amifampridine phosphate (Firdapse), 10 mg oral tablets.
  • Indication: For the symptomatic treatment of Lambert-Eaton myasthenic syndrome in adults.